



04-16-01

RECEIVED

APR 17 2001

TECH CENTER 100 501 638 416 US
Express Mail No. 100 72500

1642
#3
Response
4/21/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Siegall *et al.*

Application No.: 09/724,530

Group Art Unit: 1642

Filed: November 28, 2000

Examiner: Karen Canella

For: METHODS FOR THE TREATMENT AND
PREVENTION OF CANCER USING ANTI-
CD40 ANTIBODIES

Attorney Docket No.: 9632-012

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the outstanding Office Action dated March 14, 2001, in which the Examiner imposed a restriction requirement, please consider the following remarks. Submitted herewith are (a) a copy of a Request for Filing a Divisional Application filed concurrently with the application; (b) a copy of a Preliminary Amendment filed concurrently with the application; (c) a copy of Express Mail label no. EL 501 636 208 US; and (d) a copy of a postcard indicating receipt of (a) and (b) by the PTO on November 28, 2000.

REMARKS

The Examiner has required an election under 35 U.S.C. § 121 of one of the following inventions:

- I. Claims 1-9, 21-25, 34 and 36, drawn to a protein or antibody which binds CD40 and pharmaceutical compositions thereof, classified in class 514, subclass 2 and class 424, subclass 130.1.
- II. Claims 10-20, and 35 in part, drawn to isolated nucleic acids and recombinant cells thereof and methods for producing recombinant protein, classified in class 536, subclass 23.5 and class 435, subclasses